Not the Last Word: The Academic Inflation Reduction Act.
作者信息
Bernstein Joseph
机构信息
Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Clin Orthop Relat Res. 2024 Aug 1;482(8):1296-1301. doi: 10.1097/CORR.0000000000003171. Epub 2024 Jul 16.
Abstract
摘要
相似文献
1
Not the Last Word: The Academic Inflation Reduction Act.
Clin Orthop Relat Res. 2024 Aug 1;482(8):1296-1301. doi: 10.1097/CORR.0000000000003171. Epub 2024 Jul 16.
2
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study.
Value Health. 2025 Apr;28(4):553-561. doi: 10.1016/j.jval.2025.01.008. Epub 2025 Jan 27.
3
Out-of-Pocket Prescription Drug Savings for Medicare Beneficiaries with Asthma and COPD Under the Inflation Reduction Act.
J Gen Intern Med. 2025 Apr;40(5):1141-1149. doi: 10.1007/s11606-024-09063-4. Epub 2024 Oct 4.
4
Insurer Exits After the Inflation Reduction Act Part D Redesign.
JAMA. 2025 Jul 22;334(4):360-362. doi: 10.1001/jama.2025.7289.
5
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling Drugs.
Health Serv Res. 2025 Jul 14:e70012. doi: 10.1111/1475-6773.70012.
6
Estimated True Out-of-Pocket Cost Changes of the Inflation Reduction Act on Medicare Part D Beneficiaries with Cancer.
Value Health. 2025 Jul 15. doi: 10.1016/j.jval.2025.07.003.
7
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies.
Clin Trials. 2025 Feb;22(1):88-99. doi: 10.1177/17407745241259112. Epub 2024 Jul 24.
8
Shingles vaccination in Medicare Part D and commercial enrollees after the inflation reduction act.
Vaccine. 2025 Aug 30;62:127545. doi: 10.1016/j.vaccine.2025.127545. Epub 2025 Jul 25.
9
The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials.
Ther Innov Regul Sci. 2025 Apr 22. doi: 10.1007/s43441-025-00774-2.
10
Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development.
Drug Discov Today. 2025 Jul;30(7):104394. doi: 10.1016/j.drudis.2025.104394. Epub 2025 Jun 5.
引用本文的文献
1
Not the Last Word: Shubik Dollar Auctions and the Infinite Cost of Residency Applications.
Clin Orthop Relat Res. 2024 Dec 1;482(12):2107-2111. doi: 10.1097/CORR.0000000000003294. Epub 2024 Oct 29.
本文引用的文献
1
Artificial Intelligence in Medicine.
N Engl J Med. 2023 Mar 30;388(13):1220-1221. doi: 10.1056/NEJMe2206291.
2
Critical Assessment of the Contemporary Orthopaedic Surgery Residency Application Process.
J Bone Joint Surg Am. 2019 Nov 6;101(21):e114. doi: 10.2106/JBJS.18.00587.
3
Thousands of scientists publish a paper every five days.
Nature. 2018 Sep;561(7722):167-169. doi: 10.1038/d41586-018-06185-8.
4
The Breast Cancer Screening "Arcade" and the "Whack-A-Mole" Efforts to Reduce Access to Screening.
Semin Ultrasound CT MR. 2018 Feb;39(1):2-15. doi: 10.1053/j.sult.2017.06.002. Epub 2017 Jun 28.
5
Not the Last Word: Ending The Residency Application Arms Race-Starting with the USMLE.
Clin Orthop Relat Res. 2016 Dec;474(12):2571-2576. doi: 10.1007/s11999-016-5108-5. Epub 2016 Oct 11.
6
Editorial: ORCID is a Wonderful (But Not Required) Tool for Authors.
Clin Orthop Relat Res. 2016 May;474(5):1083-5. doi: 10.1007/s11999-016-4760-0. Epub 2016 Feb 25.
7
An index to quantify an individual's scientific research output.
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16569-72. doi: 10.1073/pnas.0507655102. Epub 2005 Nov 7.
8
Effect of weightlessness on amoebae. ANL-7409.
ANL Rep. 1967:186-7.
Zotero 插件